AU2002351077A1 - Oligonucleotides modified with novel alpha-l-rna analogues - Google Patents
Oligonucleotides modified with novel alpha-l-rna analoguesInfo
- Publication number
- AU2002351077A1 AU2002351077A1 AU2002351077A AU2002351077A AU2002351077A1 AU 2002351077 A1 AU2002351077 A1 AU 2002351077A1 AU 2002351077 A AU2002351077 A AU 2002351077A AU 2002351077 A AU2002351077 A AU 2002351077A AU 2002351077 A1 AU2002351077 A1 AU 2002351077A1
- Authority
- AU
- Australia
- Prior art keywords
- novel alpha
- oligonucleotides modified
- rna analogues
- analogues
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/337—Chemical structure of the base in alpha-anomeric form
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33744701P | 2001-11-05 | 2001-11-05 | |
| DKPA200101640 | 2001-11-05 | ||
| US60/337,447 | 2001-11-05 | ||
| DKPA200101640 | 2001-11-05 | ||
| PCT/IB2002/005080 WO2003039523A2 (en) | 2001-11-05 | 2002-11-05 | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002351077A1 true AU2002351077A1 (en) | 2003-05-19 |
Family
ID=29585604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002351077A Abandoned AU2002351077A1 (en) | 2001-11-05 | 2002-11-05 | Oligonucleotides modified with novel alpha-l-rna analogues |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002351077A1 (en) |
| WO (1) | WO2003039523A2 (en) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE44779E1 (en) | 1997-03-07 | 2014-02-25 | Santaris Pharma A/S | Bicyclonucleoside and oligonucleotide analogues |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EA007867B1 (en) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Methods and compositions for treating flaviviruses and pestiviruses |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| CN1678326A (en) | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 2'-C-methyl-3'-O-L-valine ester ribofuranocytidine for the treatment of flavivirus infection |
| DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
| PL377287A1 (en) | 2002-12-12 | 2006-01-23 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| CA2529793C (en) * | 2003-06-20 | 2015-05-05 | Exiqon A/S | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same |
| ATE553216T1 (en) | 2003-06-20 | 2012-04-15 | Exiqon As | PROBE, LIBRARIES AND KITS FOR ANALYZING NUCLEIC ACID MIXTURES AND METHODS FOR THEIR CONSTRUCTION |
| JP2008510748A (en) | 2004-08-23 | 2008-04-10 | エフ.ホフマン−ラ ロシュ アーゲー | Antiviral 4'-azido-nucleoside |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| CN101979397B (en) | 2006-10-10 | 2013-11-06 | 美迪维尔公司 | HCV nucleoside inhibitor |
| ATE551061T1 (en) * | 2006-11-13 | 2012-04-15 | Santaris Pharma As | LNA NUCLEOSIDE PHOSPHORAMIDATE |
| BRPI0817605A2 (en) | 2007-10-03 | 2017-05-09 | Quark Pharmaceuticals Inc | new siren structures |
| WO2009079456A2 (en) | 2007-12-14 | 2009-06-25 | Minitube Of America, Inc. | Gender-specific separation of sperm cells and embryos |
| US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
| WO2010108140A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| WO2011032034A2 (en) | 2009-09-10 | 2011-03-17 | University Of Idaho | Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids |
| CA2811333C (en) | 2010-09-16 | 2020-05-12 | Gen-Probe Incorporated | Capture probes immobilizable via l-nucleotide tail |
| US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| CN103209987B (en) | 2010-09-22 | 2017-06-06 | 艾丽奥斯生物制药有限公司 | substituted nucleotide analogs |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| RU2014106024A (en) | 2011-07-19 | 2015-08-27 | Юниверсити Оф Айдахо | OPTIONS FOR IMPLEMENTING THE PROBE AND METHODS OF DIRECTED ACTION FOR NUCLEIC ACIDS |
| SI2794627T1 (en) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Substituted phosphorothioate nucleotide analogs |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| TW201408688A (en) | 2012-05-25 | 2014-03-01 | Janssen R & D Ireland | Uracyl spirooxetane nucleosides |
| WO2014033617A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | 2'-ethynyl nucleoside derivatives for treatment of viral infections |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | ELIMINATING DNA FRAGMENTS IN METHODS OF PRODUCING MRNA |
| EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| RS62529B1 (en) | 2013-07-11 | 2021-11-30 | Modernatx Inc | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
| SG11201602595TA (en) | 2013-10-11 | 2016-04-28 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| JP2017522028A (en) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Circular polynucleotide |
| RU2764767C2 (en) | 2015-03-06 | 2022-01-21 | Атеа Фармасьютикалс, Инк. | β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV |
| TWI870767B (en) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
| CN105085356B (en) * | 2015-08-26 | 2018-09-07 | 中国科学院化学研究所 | Small paper mulberry alkaloid compound and its preparation method and application |
| CN105085357B (en) * | 2015-08-26 | 2018-04-13 | 中国科学院化学研究所 | Small paper mulberry alkaloid compound and its preparation method and application |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| PL3350333T3 (en) | 2015-09-17 | 2022-03-07 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
| MA43671A (en) | 2016-03-10 | 2018-11-28 | Janssen Pharmaceutica Nv | ANALOGUES OF SUBSTITUTED NUCLEOSIDES FOR USE AS PRMT5 INHIBITORS |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| WO2018035380A1 (en) | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| CN116036114A (en) | 2016-09-07 | 2023-05-02 | 阿堤亚制药公司 | 2'-substituted-N6-substituted purine nucleotides for RNA virus therapy |
| KR102531344B1 (en) | 2016-10-03 | 2023-05-10 | 얀센 파마슈티카 엔.브이. | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors |
| CA3048033C (en) | 2017-02-01 | 2023-06-20 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
| PE20191359A1 (en) | 2017-02-27 | 2019-10-01 | Janssen Pharmaceutica Nv | USE OF BIOMARKERS IN THE IDENTIFICATION OF PATIENTS WITH CANCER WHO WILL BE SENSITIVE TO TREATMENT WITH A PRMT5 INHIBITOR |
| EP3645546A4 (en) | 2017-06-30 | 2021-12-01 | Solstice Biologics, Ltd. | CHIRAL PHOSPHORAMIDITE AIDS AND METHOD FOR THEIR USE |
| CN107973830B (en) * | 2017-11-23 | 2020-06-05 | 中国科学院成都生物研究所 | Total synthesis method of neooxytocin |
| MA51004A (en) | 2017-12-08 | 2020-10-14 | Janssen Pharmaceutica Nv | NEW SPIROBICYCLIC ANALOGUES |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| EP3861118A4 (en) * | 2018-10-05 | 2023-11-15 | Ionis Pharmaceuticals, Inc. | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF |
| KR20210145787A (en) | 2019-04-02 | 2021-12-02 | 알리고스 테라퓨틱스 인코포레이티드 | Compounds targeting PRMT5 |
| TW202112375A (en) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | Methods of treating cancer using prmt5 inhibitors |
| US20230159922A1 (en) * | 2019-08-15 | 2023-05-25 | Ionis Pharmaceuticals, Inc. | Modified oligomeric compounds and uses thereof |
| CN115038790B (en) * | 2019-11-27 | 2024-06-21 | 阿尔尼拉姆医药品有限公司 | Synthesis of 3’-RNA oligonucleotides |
| TWI775313B (en) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | Antiviral compounds |
| TWI883391B (en) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | Antiviral compounds |
| SI4106876T1 (en) | 2020-02-18 | 2025-11-28 | Gilead Sciences, Inc. | Antiviral compounds |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| JP7688152B2 (en) | 2021-04-16 | 2025-06-03 | ギリアード サイエンシーズ, インコーポレイテッド | Method for preparing carbanucleosides using amides |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Advantageous anti-hcv combination therapy |
| EP4355756A4 (en) | 2021-06-18 | 2025-08-13 | Hongene Biotech Corp | Functionalized N-acetylgalactosamine nucleosides |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| JP2024532271A (en) | 2021-08-30 | 2024-09-05 | ホンジーン バイオテック コーポレイション | Functionalized N-acetylgalactosamine analogs |
| EP4448540A1 (en) | 2021-12-15 | 2024-10-23 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2636633A1 (en) * | 1988-09-20 | 1990-03-23 | Centre Nat Rech Scient | PROCESS FOR SYNTHESIS OF ALPHA OLIGORIBONUCLEOTIDES AND COMPOUNDS USEFUL IN THE PROCESS |
| US5559101A (en) * | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
| AU9063398A (en) * | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| WO2000056748A1 (en) * | 1999-03-18 | 2000-09-28 | Exiqon A/S | Xylo-lna analogues |
| DK1178999T3 (en) * | 1999-05-04 | 2007-08-06 | Santaris Pharma As | L-ribo-LNA analogues |
| AU7406700A (en) * | 1999-10-04 | 2001-05-10 | Exiqon A/S | Design of high affinity rnase h recruiting oligonucleotide |
-
2002
- 2002-11-05 AU AU2002351077A patent/AU2002351077A1/en not_active Abandoned
- 2002-11-05 WO PCT/IB2002/005080 patent/WO2003039523A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003039523A3 (en) | 2003-12-04 |
| WO2003039523A2 (en) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002351077A1 (en) | Oligonucleotides modified with novel alpha-l-rna analogues | |
| GB0128526D0 (en) | Nucleotide analogues | |
| AU2002358463A1 (en) | Oligonucleotide analogues comprising intercalator pseudonucleotides | |
| AU2002313565A1 (en) | Putter-heads | |
| AU2002319532A1 (en) | Feeding-bottles | |
| AU2002313943A1 (en) | Electromobile | |
| AU2002226571A1 (en) | Biligands | |
| AU2001100406A4 (en) | DriverSMS | |
| AU2002313073A1 (en) | Phytocystatin | |
| AU2002257925A1 (en) | Numberplates | |
| AU2002333362A1 (en) | Flat structure | |
| AU2001100522A4 (en) | e-Trans | |
| AU2001100214A4 (en) | Dolly-trolley | |
| AU2001100338A4 (en) | Sunglove | |
| AU2002100746A4 (en) | Adrail | |
| AU2001100532A4 (en) | FonePark | |
| AU2002302458A1 (en) | Paint-can with bruswiper | |
| AU2002235828A1 (en) | Transom-mullion structure | |
| AU2002258273A1 (en) | Drain-outlet structure | |
| AU2002246370A1 (en) | Flat unit structure | |
| AUPR383801A0 (en) | Increased superannuation | |
| AU2002316748A1 (en) | S-6-hydroxy-buspirone | |
| AU2002302413A1 (en) | Tryptase-inhibitors | |
| AU2002321547A1 (en) | Beta-ketophosphonates | |
| AU2002322180A1 (en) | Lipophorins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |